NKTR | tickerfilter.com

Fundamental analysis

52%

Profitability 0%

Dept financing 50%

Liquidity 68%

Performance 100%

Company vs Stock growth

+ Add row to compare

Performance

5 Days

15.67%

1 Month

32.04%

3 Months

168.71%

6 Months

58.89%

1 Year

14,683.13%

2 Year

7,117.65%

Key data

Stock price

$98.16

P/E Ratio

N/A

DAY RANGE

$96.23 - $106.42

EPS

-$7.20

52 WEEK RANGE

$0.57 - $109.00

52 WEEK CHANGE

$14,213.21

MARKET CAP

0.000

YIELD

N/A

SHARES OUTSTANDING

28.688 M

DIVIDEND

N/A

EX-DIVIDEND DATE

N/A

NEXT EARNINGS DATE

05-08-2025

BETA

2.59

PUBLIC FLOAT

AVERAGE 10 VOLUME

$1,360,496

AVERAGE 30 VOLUME

$991,300

Company detail

CEO: Howard W. Robin
Region: US
Website: nektar.com
Employees: 220
IPO year: 1994

Issue type: Common Stock
Market: XNAS
Industry: Pharmaceutical Products/Pharmaceutical Preparations
Sector: Manufacturing

Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing medicines in areas of unmet medical need in the United States and internationally. The company's products include Bempegaldesleukin, which is in phase 3 clinical trial to treat metastatic melanoma, renal cell carcinoma, muscle-invasive bladder cancer, squamous cell carcinomas of the head and neck, and adjuvant melanoma. It is also developing NKTR-358, a cytokine Treg stimulant, in phase 2 clinical trial for the treatment of systemic lupus erythematosus

NKTR - NEKTAR THERAPEUTICS